Document is current
Any future updates will be listed below
-
Authors
Raposo Pereira, Filipa https://orcid.org/0000-0001-6199-7164
Chaumon, Maximilien
Dubois, Bruno
Bakardjian, Hovagim
Bahrami, Mahsa
Habert, Marie-Odile
Andrade, Katia
Younsi, Nadjia
La Corte, Valentina
George, Nathalie
,
-
Funding
Funding for this research was provided by:
Fondation pour la Recherche sur Alzheimer (ePARAD)
Inserm Transfert (IDRCB: 2012-A01731-42, protocol nb. C12-59)
Investissements d’avenir (ANR-10- IAIHU-06)
Pfizer
Fondation Plan-Alzheimer
Avid
- License Information
-
More Information
Article History
Received: 25 September 2024
Revised: 22 November 2024
Accepted: 24 November 2024
First Online: 16 December 2024
Declarations
:
: The authors declare no competing interests that are relevant to the content of this article. The funding bodies had no role in the study design, in the data analysis and interpretation, or in the article writing.
: All aspects of this study were designed in full compliance with the French law n° 2004–806 (9th August 2004), the Good Clinical Practice principles (I.C.H version 4 of 1st May 1996 and the decision of 24th November 2006), the guidelines of the Helsinki Declaration (Ethical Principles for Medical Research involving Human Subjects, Tokyo, 2004), and the human ERP research technical guidelines []. The INSIGHT-PreAD study protocol was approved by the ethics committee of the Pitié-Salpêtrière Hospital (IDRCB: 2012-A01731-42) and the present project was approved by the INSIGHT-preAD scientific committee. All the clinicians and neuropsychologists involved in the acquisition of data from the INSGHT cohort had authorization for using all the tests include on the study.
: After study conditions were presented, a signed informed consent and willingness to commit to the longevity of the project was obtained from all individual participants included in the study.
: The authors confirm that human research participants provided informed consent for publication of the images present in the article.
